Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Centrosomal protein of 162 kDa (CEP162) is a centrosome- and microtubule-associated protein essential for the assembly of the ciliary transition zone (TZ), a key region at the base of cilia that regulates compartmentalization and signaling[1][2]. CEP162 is "pre-tethered" at centriole distal ends prior to ciliogenesis, where it directly binds to axonemal microtubules through its coiled-coil domains and promotes the recruitment of core transition zone components (e.g., CEP290, NPHP1, Tctn2)[1]. Loss of CEP162 disrupts TZ assembly and arrests ciliogenesis, resulting in cellular and tissue defects. In the retina, biallelic truncating mutations in CEP162 impair ciliary function specifically in photoreceptors, leading to late-onset retinitis pigmentosa, while maintaining partial neuronal differentiation functions[2]. CEP162 is not currently considered a direct therapeutic target, and no drugs are known to interact with it. Its primary biomedical relevance is as a causative gene for certain retinal ciliopathies and as a biomarker for associated inherited retinopathies[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Centrosomal protein of 162 kDa (CEP162).